Description

                      buy Melanotan II

       buy Melanotan II (MT-2) is a synthetic cyclic lactam analog of the naturally occurring melanocyte-stimulating hormone (α-MSH). Originally developed at the University of Arizona as a potential therapeutic agent for skin cancer prevention and sexual dysfunction, this peptide has garnered significant attention in research settings for its dual action on melanocortin receptors. Presented in a sterile 10mg lyophilized format, this product is intended for laboratory research and scientific investigation only—not for human consumption, diagnostics, or veterinary use.

Chemical & Structural Characteristics for buy Melanotan II

Unlike its linear predecessor Melanotan I (afamelanotide), Melanotan II features a lactam bridge that confers cyclic conformation. This structural modification enhances metabolic stability, receptor binding affinity, and biological half-life. The cyclization reduces enzymatic degradation in biological matrices, making MT-2 particularly suitable for in vivo pharmacokinetic studies. With a molecular weight of 1024.2 g/mol and high purity (≥99% by reverse-phase HPLC), each 10mg vial contains a precisely measured dose of lyophilized peptide, free from residual solvents, endotoxins, or aggregation byproducts. Mass spectrometry (MALDI-TOF) validation is available upon request.

Mechanism of Action (Research Context)

Melanotan II functions primarily as a non-selective melanocortin receptor agonist, with high affinity for MC1R, MC3R, MC4R, and moderate activity at MC5R. Upon receptor binding, it activates the cyclic AMP (cAMP) signaling pathway via Gs protein coupling.

• MC1R (Melanocortin 1 Receptor): Found on melanocytes, MC1R activation stimulates melanogenesis—the production of eumelanin (brown/black pigment) via tyrosinase upregulation. This is the primary pathway investigated in photoprotection studies, as increased eumelanin provides natural UV absorption and free radical scavenging.

• MC4R (Melanocortin 4 Receptor): Expressed in the hypothalamus, MC4R mediates satiety and energy homeostasis. MT-2’s agonist activity at MC4R has been studied for appetite suppression and metabolic regulation.

• MC3R & MC5R: These receptors are involved in energy partitioning, natriuresis, and exocrine gland function, though they are secondary targets of MT-2.

Notably, MT-2 has a well-documented off-target effect on erectile tissue via central melanocortinergic pathways, specifically through activation of paraventricular nucleus (PVN) MC4R, leading to increased nitric oxide synthase (NOS) activity. This mechanism is distinct from PDE5 inhibitors and has been the subject of multiple preclinical investigations into arousal and erectile function.

Primary Research Applications

1. Photoprotection & Pigmentation Research

The most widely studied application of MT-2 is its ability to induce a UV-independent tan. In controlled laboratory models (murine and ex vivo human skin explants), MT-2 administration results in dose-dependent darkening of the skin, fur, and hair within 7–14 days. This effect is mediated by increased eumelanin-to-pheomelanin ratio, which is of interest in studies of:

• UV radiation-induced DNA damage (cyclobutane pyrimidine dimers)

• Basal cell carcinoma and melanoma risk factors

• Skin phototype modulation

• Drug-induced photosensitivity

Researchers note that MT-2 can produce pigmentation in fair-skinned subjects without UV exposure, though combined UV or narrowband UVB is often used to accelerate and deepen the effect in controlled trials.

2. Sexual Function & Reproductive Neurobiology

MT-2’s ability to induce spontaneous erections in rodent models has been documented since the early 2000s. The peptide acts centrally, bypassing peripheral vascular pathology. Research applications include:

• Mapping melanocortin pathways in the hypothalamus and brainstem

• Comparing efficacy with apomorphine and other dopamine agonists

• Investigating female sexual arousal (increased genital blood flow in rat models)

• Studying spinal reflex pathways involved in copulatory behavior

The effect is dose-dependent, with an ED₅₀ for erectile response in rats ranging from 0.03 to 0.1 mg/kg subcutaneous. This response is blocked by MC4R antagonists (e.g., HS024), confirming receptor specificity.

3. Appetite & Metabolic Research

MC4R agonism by MT-2 suppresses food intake in overnight-fasted animals, with effects lasting 6–12 hours. This property has been explored in:

• Obesity and cachexia models (comparison with semaglutide and other GLP-1 analogs)

• Hypothalamic signaling cross-talk (melanocortin vs. agouti-related peptide pathways)

• Binge eating disorder mechanisms

Unlike α-MSH, MT-2’s cyclic structure confers resistance to aminopeptidases, making it a more reliable tool for prolonged infusion studies.

4. Libido & Addiction Neurochemistry

Emerging research has investigated MT-2’s effects on dopaminergic reward pathways. Some studies suggest modulation of ventral tegmental area (VTA) activity and nucleus accumbens dopamine release, though this is not a primary application. Caution is advised, as melanocortin-dopamine interactions remain incompletely mapped.

Handling & Reconstitution Protocol (For Laboratory Use)

The 10mg lyophilized powder is supplied in a 10mL sterile glass vial with a butyl rubber stopper and aluminum crimp seal. To reconstitute:

1. Required materials: Sterile bacteriostatic water for injection (0.9% benzyl alcohol), 3mL syringe, 18G filter needle (for withdrawal), and 27G–30G insulin syringe (for dosing).

2. Calculation for 10mg vial: Add 2mL of diluent to achieve a concentration of 5mg/mL. For finer dosing (e.g., 0.5mg per 0.1mL), add 4mL diluent → 2.5mg/mL; or 10mL diluent → 1mg/mL.

3. Technique: Wipe the vial stopper with 70% isopropyl alcohol. Draw diluent into syringe. Insert needle through stopper center, angle slightly to avoid core holing. Inject diluent slowly against the vial wall—never directly onto the powder to prevent denaturation. Swirl gently (do not shake) until fully dissolved. Clear, colorless solution indicates proper reconstitution. Any turbidity or particulates indicates degradation.

4. Aliquoting: Pre-load multiple sterile insulin syringes with desired dose (e.g., 0.1mL = 250mcg if 2.5mg/mL). Freeze syringes at -20°C for up to 3 months. Thaw only once.

Stability & Storage Guidelines

• Lyophilized (unopened): 24 months from date of manufacture when stored at -18°C to -25°C. Avoid freeze-thaw cycles. Desiccated storage is optimal.

• Reconstituted (refrigerated): Stable for 14 days at +2°C to +8°C. Do not leave at room temperature for >2 hours.

• Reconstituted (frozen): Stable for 3 months at -20°C in individual syringes. Thaw in refrigerator; do not refreeze.

• Signs of degradation: Loss of pigmenting efficacy, increased injection-site erythema, presence of precipitate, or pH shift (reconstituted solution pH should be 4.5–6.5).

Safety & Handling Precautions (Laboratory Only)

• Personal protective equipment (PPE): Always wear nitrile gloves, lab coat, and safety goggles when handling lyophilized powder or reconstituted solution. MT-2 is an active peptide that can be absorbed through mucous membranes or broken skin.

• Inhalation risk: Do not handle powder in open air. Weighing or transfer should occur in a certified fume hood or biosafety cabinet.

• Accidental exposure: In case of skin contact, wash immediately with soap and copious water. For eye exposure, rinse with saline for 15 minutes and seek medical evaluation. If accidentally injected (e.g., needle stick), monitor for systemic effects including nausea, facial flushing, yawning, stretching, and spontaneous erections. These effects are typically self-limiting (30–90 minutes) but warrant reporting to a safety officer.

• Disposal: Deactivate peptide residues with 10% bleach solution for 30 minutes before disposing as biohazardous waste. Empty vials may be autoclaved or chemically decontaminated.

Known Research Limitations & Side Effect Profile (In Vivo Models)

While MT-2 is a valuable research tool, investigators should be aware of its documented off-target effects in animal models:

• Nausea & malaise: Observed in 60–80% of rodent and canine subjects within 15–30 minutes of dosing, lasting 20–60 minutes. This is believed to be mediated by MC4R activation in the area postrema (chemoreceptor trigger zone). Dose titration starting at 0.01 mg/kg can reduce severity.

• Facial flushing & yawning: Central melanocortin activation of the paraventricular nucleus leads to oxytocin release, producing yawning and spontaneous stretching. This is a pharmacodynamic marker of MC4R engagement.

• Mole darkening & nevi modulation: In pigmented animals, existing nevi may darken disproportionately. Long-term studies (6+ months) have reported de novo melanocytic hyperplasia in some strains, though malignant transformation has not been consistently demonstrated.

• Blood pressure changes: Acute hypotension (10–15 mmHg decrease) has been noted following high doses (≥0.3 mg/kg) in normotensive rats due to MC3R-mediated natriuresis.

• Appetite suppression: Significant reduction in 24-hour food intake (up to 40%) occurs at therapeutic doses. This may confound metabolic studies if not controlled for.

Quality Assurance & Technical Support

Each batch of Melanotan II (MT-2) 10mg undergoes the following quality control tests:

• HPLC (purity ≥99%)

• Mass spectrometry (observed M+1 = 1025.2)

• Endotoxin (≤1.0 EU/mg)

• Sterility (USP <71>)

• Residual solvent analysis (by GC)

A Certificate of Analysis (COA) is available for download using the lot number printed on each vial label. For technical inquiries—including reconstitution troubleshooting, receptor binding assays, or in vivo protocol optimization—our scientific support team is available via email (research@domain.com) with a typical response time of 24–48 hours.